Efficacy of Antiviral Therapy in HBsAg-Positive Pregnant Women to Reduce Mother-to-Infant Transmission of Hepatitis B Virus

摘要

Background and Objectives Hepatitis B is a major health concern in Asia. Chronic hepatitis B virus (HBV) infection may cause hepatic cirrhosis and liver cancer. HBV is transmitted horizontally through blood and blood products and vertically from mother to infant. Perinatal infection is the main route of transmission in regions with high prevalence of hepatitis B surface antigen (HbsAg) carriage, and perinatal transmission leads to high rates of chronic infection. Therefore, it is important to prevent mother-to-child transmission (MTCT) of HBV1. The present study aims at comparing the use of antivirals (lamivudine vs tenofovir) in reducing MTCT. Materials and Methods A total of 60 HbsAg-positive pregnant women were enrolled in the prospective study to test the efficacy of antiviral (lamivudine vs tenofovir—category B drug) to reduce mother-to-child transmission and monitor hepatitis B viral status in infant. HbsAg-positive pregnant women aged 18–43?years at gestational age between 28 and 32?weeks were followed up. They were tested for HBsAg, liver function test and HBeAg. In whom HbeAg was positive, HBV viral load was tested. Sixty patients with high viral load (6?log copies/ml) were recruited in the study. Alternate patients were randomized into two groups. Group A comprised 31 subjects treated with lamivudine 100?mg daily starting from 28 to 32?weeks of gestation (third trimester) and continued to 1?month after delivery. Group B comprised 29 pregnant women who were treated with tenofovir 300?mg daily from 28 to 32?weeks of gestation and continued to 1?month post-partum. The newborn babies were given HBIG within 24?h after delivery and HBV vaccines at 0, 1 and 6?months. HBsAg infectivity was tested in the infant at 1?year after birth. Results Antivirals, lamivudine/tenofovir treatment in HBV carrier mothers from 28?weeks of gestation along with active and passive immunization of new born may interrupt MTCT of HBV efficiently. Tenofovir, category B drug, is more effective in preventing transmission of HBV infection to infants ( p =?0.004).